Singh MP, Hoerste GMZ, Hu W, Mausberg AK, Cravens PD, Eagar T, Löber S, Klingenstein R, Gmeiner P, Korth C, Kieseier BC, Stueve O (2009)
Publication Type: Journal article
Publication year: 2009
Publisher: Elsevier
Book Volume: 215
Pages Range: 397-400
DOI: 10.1016/j.expneurol.2008.10.001
Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNγ and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.
APA:
Singh, M.P., Hoerste, G.M.Z., Hu, W., Mausberg, A.K., Cravens, P.D., Eagar, T.,... Stueve, O. (2009). Quinpramine is a novel compound effective in ameliorating brain autoimmune disease. Experimental Neurology, 215, 397-400. https://doi.org/10.1016/j.expneurol.2008.10.001
MLA:
Singh, Mahendra P., et al. "Quinpramine is a novel compound effective in ameliorating brain autoimmune disease." Experimental Neurology 215 (2009): 397-400.
BibTeX: Download